1. Pathway from TDP-43-Related Pathology to Neuronal Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.
- Author
-
Riku Y, Seilhean D, Duyckaerts C, Boluda S, Iguchi Y, Ishigaki S, Iwasaki Y, Yoshida M, Sobue G, and Katsuno M
- Subjects
- Amyotrophic Lateral Sclerosis diagnosis, Biomarkers, DNA-Binding Proteins genetics, Frontotemporal Lobar Degeneration diagnosis, Gain of Function Mutation, Humans, Immunohistochemistry, Loss of Function Mutation, Protein Aggregation, Pathological genetics, Protein Aggregation, Pathological metabolism, Protein Binding, tau Proteins metabolism, Amyotrophic Lateral Sclerosis etiology, Amyotrophic Lateral Sclerosis metabolism, DNA-Binding Proteins metabolism, Disease Susceptibility, Frontotemporal Lobar Degeneration etiology, Frontotemporal Lobar Degeneration metabolism, Neurons metabolism, Signal Transduction
- Abstract
Transactivation response DNA binding protein 43 kDa (TDP-43) is known to be a pathologic protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). TDP-43 is normally a nuclear protein, but affected neurons of ALS or FTLD patients exhibit mislocalization of nuclear TDP-43 and cytoplasmic inclusions. Basic studies have suggested gain-of-neurotoxicity of aggregated TDP-43 or loss-of-function of intrinsic, nuclear TDP-43. It has also been hypothesized that the aggregated TDP-43 functions as a propagation seed of TDP-43 pathology. However, a mechanistic discrepancy between the TDP-43 pathology and neuronal dysfunctions remains. This article aims to review the observations of TDP-43 pathology in autopsied ALS and FTLD patients and address pathways of neuronal dysfunction related to the neuropathological findings, focusing on impaired clearance of TDP-43 and synaptic alterations in TDP-43-related ALS and FTLD. The former may be relevant to intraneuronal aggregation of TDP-43 and exocytosis of propagation seeds, whereas the latter may be related to neuronal dysfunction induced by TDP-43 pathology. Successful strategies of disease-modifying therapy might arise from further investigation of these subcellular alterations.
- Published
- 2021
- Full Text
- View/download PDF